Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 774-784

  Woodburn, Kathryn W ^a,g   Fong, Kei Lai ^b   Wilson, Susan D ^c,h   Sloneker, Steven ^d   Strzemienski, Paul ^e   Solon, Eric ^e   Moriya, Yuu ^f   Tagawa, Yoshihiko ^f  

^a AFFYMAX RESEARCH INSTITUTE   (United States)

^b Accellient Partners LLC   (United States)

^c Aclairo Pharmaceutical Development Group Inc   (United States)

^d Calvert Laboratories Inc   (United States)

^e QPS LLC   (United States)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^g Aero Dap Therapeutics LLC   (United States)

^h Aclairo PDG Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINESATIDE; PEGINESATIDE C 14; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BONE MARROW; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; ERYTHROPOIESIS; GLOMERULUS; HAPLORHINI; HEMATOPOIETIC TISSUE; KIDNEY CELL; KIDNEY CORTEX; KIDNEY INTERSTITIUM; KIDNEY MEDULLA; MALE; MOLECULAR WEIGHT; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; URINARY EXCRETION;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BIOLOGICAL AVAILABILITY; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIESIS; HEMATINICS; KIDNEY; MACACA FASCICULARIS; MALE; PEPTIDES; SPLEEN;

PRIMATES;

EID: 84875857269     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048033     Document Type: Article

References (34)

1. Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, Narhi L, and Elliott S (2009) Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci 98:2198-2211.
2. Caliceti P and Veronese FM (2003) Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277.
3. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, and Boytos CM, et al. (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276:1696-1699.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, and Green JM, et al. (2006) Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 34:1303-1311.
6. Greaves P and Faccini JM (1992) Haemopoietic and lymphatic systems, in Rat Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies 2nd ed (Greaves P, Faccini JM, eds) pp 43-66, Elsevier, Amsterdam.
7. Green J, Leu K, Fan Q, Frederick B, Mortensen R, Young P, Schatz P, Woodburn K, and Holmes C (2011) In vivo erythropoietic activity of peginesatide correlates with erythropoietin receptor residence time and plasma half life [Abstract]. J Am Soc Nephrol 22:674A.
8. Guiotto A, Canevari M, Pozzobon M, Moro S, Orsolini P, and Veronese FM (2004) Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg Med Chem 12:5031-5037.
9. Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221.
10. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, and Sugiyama Y (1997) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520-527.
11. Kruse A, Uehlinger DE, Gotch F, Kotanko P, and Levin NW (2008) Red blood cell lifespan, erythropoiesis and hemoglobin control. Contrib Nephrol 161:247-254.
12. Li S, Foley RN, and Collins AJ (2004) Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 65:1864-1869.
13. Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, and Ratcliffe PJ (1997) Sites of erythropoietin production. Kidney Int 51:393-401.
14. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, and Eckardt KU (2009) A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361:1848-1855.
15. Moore DA (2000) Hematology of nonhuman primates, in Schlam's Veterinary Hematology, 5th ed, pp 1133-1144, Lippincott Williams & Wilkins, Philadelphia.
16. Okasaki K, Funato M, Kashima M, Nakama K, Inoue T, Hiura M, Kato Y, and Nagata R (2002) Twenty-six-week repeat-dose toxicity study of a recombinant human granulocyte colonystimulating factor derivative (nartograstim) in cynomolgus monkeys. Toxicol Sci 65:246-255.
17. O'Malley DP, Kim YS, Perkins SL, Baldridge LA, Juliar BE, and Orazi A (2005) Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders. Mod Pathol 18:1550-1561.
18. Porter CJ, Edwards GA, and Charman SA (2001) Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 50:157-171.
19. Silverberg D (2003) Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 18 (S2):7-12.
20. Solon EG (2012) Use of radioactive compounds and autoradiography to determine drug tissue distribution. Chem Res Toxicol 25:543-555.
21. Solon EG, Schweitzer A, Stoecki M, and Prideaux B (2010) Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development. AAPS J 12:11-26.
22. Starost MF, Hill LR, Nehete PN, and Sastry KJ (2004) Extramedullary hematopoiesis in the mandibular lymph node of simian-human immunodeficiency virus-infected rhesus monkeys (Macaca mulatta): a report of three cases. Vet Pathol 41:186-190.
23. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, and Duliege AM (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, doseescalation study in healthy volunteers. Blood 108:1830-1834.
24. Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, and Gray SJ; European/Australian NESP 970200 Study Group (2002) Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167-2175.
25. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, and Smith D (2007) PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35:9-16.
26. Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, Moore MA, O'Reilly RJ, and Souza LM (1987) Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 165:941-948.
27. Westenfelder C, Biddle DL, and Baranowski RL (1999) Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55:808-820.
28. Woo S, Krzyzanski W, and Jusko WJ (2007) Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 34:849-868.
29. Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, and Schatz PJ (2007) Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 35:1201-1208.
30. Woodburn KW, Schatz PJ, Fong K-L, Wilson SD, Ferrell T, Spainhour CB, and Norton D (2008a) Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys. Drug Chem Toxicol 31:229-244.
31. Woodburn KW, Wilson SD, Fong K-L, Schatz PJ, Ferrell T, Spainhour CB, and Norton D (2008b) Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica 93:1376-1379.
32. Woodburn KW, Wilson SD, Fong K-L, Schatz PJ, Spainhour CB, and Norton D (2009) Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Basic Clin Pharmacol Toxicol 104:155-163.
33. Woodburn KW, Schatz PJ, Wilson S, Fong K-L, Wagner VO, Gudi R, Krsmanovic L, Paranjpe M, and Shah SA (2011) Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice. Drug Chem Toxicol 34:240-249.
34. Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, and Tagawa Y (2012) Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica 42:660-670.